Several members of both the Rb and p53 pathways are classified as tumour suppressor genes, based on their frequent loss-of-function via deletion, intragenic mutations (e.g., p53 is mutated in almost 40% of all human cancers) or epigenetic alterations that compromise these tumour suppressor pathways. The gene discussed is TP53; the disease is cancer.